Fundraising Fox
Diagonal Therapeutics
Watertown, US · Founded 2022 · 38 employees on LinkedIn · 7 known investors
Find your way into Diagonal Therapeutics
Sign up to see every warm intro you have to Diagonal Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Diagonal Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.
Founders & leadership
Investors · 7
How we know: Atlas Venture's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RV Invest GmbH's portfolio page · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Frequently asked questions
- What does Diagonal Therapeutics do?
- Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.
- Who are Diagonal Therapeutics's investors?
- Diagonal Therapeutics's investors include Atlas Venture, EcoR1 Capital, Frazier Life Sciences, RA Capital, RV Invest GmbH, Sanofi Ventures, Viking Global.
- Where is Diagonal Therapeutics headquartered?
- Diagonal Therapeutics is headquartered in Watertown, US.